Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

NEW YORK, July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "RLMD."

The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression.  NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:

Tim McCarthy  
LifeSci Advisors  

For Media Inquiries:

FischTank PR 

Cision View original content to download multimedia:

SOURCE Relmada Therapeutics, Inc.